Sanofi (NASDAQ:SNY) Short Interest Down 17.4% in December

Sanofi (NASDAQ:SNY - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 3,740,000 shares, a decline of 17.4% from the November 30th total of 4,530,000 shares. Currently, 0.2% of the company's shares are short sold. Based on an average daily volume of 2,210,000 shares, the short-interest ratio is currently 1.7 days.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Citigroup upgraded Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Sanofi currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.50.

Sanofi Stock Up 0.6 %

SNY stock traded up $0.30 during trading on Friday, hitting $48.73. 2,221,822 shares of the company's stock traded hands, compared to its average volume of 2,096,043. The firm has a market capitalization of $123.67 billion, a P/E ratio of 24.86, a PEG ratio of 1.23 and a beta of 0.58. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The business has a fifty day simple moving average of $49.64 and a two-hundred day simple moving average of $52.03.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business's revenue was up 12.3% compared to the same quarter last year. During the same period last year, the business posted $2.55 EPS. Sell-side analysts anticipate that Sanofi will post 4.06 EPS for the current year.

Hedge Funds Weigh In On Sanofi

A number of large investors have recently added to or reduced their stakes in the company. Barrow Hanley Mewhinney & Strauss LLC increased its position in shares of Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company's stock worth $288,381,000 after purchasing an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC increased its position in Sanofi by 1,153.1% during the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company's stock valued at $121,605,000 after buying an additional 2,306,286 shares in the last quarter. Jennison Associates LLC raised its stake in Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company's stock valued at $109,753,000 after buying an additional 1,720,972 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in Sanofi by 28,890.2% in the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company's stock worth $82,366,000 after acquiring an additional 1,424,289 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of Sanofi by 26.5% during the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company's stock worth $155,950,000 after acquiring an additional 673,172 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.